SK Hynix Shares Fall as Workers Reject Wage Deal 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tesla Raises Cybertruck Prices by $5,000 in US 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Add as a preferred source on Google
BEVERLY, Mass. and TORONTO, May 01, 2018 -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly
traded and private companies through presentations and private meetings.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
For more information, please contact:
David Wolf, President & CEO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Michael Bruns, CFO
Hamilton Thorne Ltd.
978-921-2050
[email protected]
Glen Akselrod
Bristol Investor Relations
905-326-1888
[email protected]
